Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2016 Nov 20

PMID 27864751

Citations 26

Authors

Bosco Paes

Brigitte Fauroux

Josep Figueras-Aloy

Louis Bont

Paul A Checchia

Eric A F Simoes

Paolo Manzoni

Xavier Carbonell-Estrany

Affiliations

Soon will be listed here.

Abstract

Introduction: The REGAL (RSV evidence-a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD).

Methods: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among infants with CLD/BPD who were not prophylaxed, as well as studies reporting RSV-associated morbidity, mortality, and healthcare costs, were included. Burdens of disease data were compared with preterm infants without CLD/BPD, other high-risk groups and term infants. Study quality and strength of evidence (SOE) were graded using recognized criteria.

Results: A total of 1837 studies were identified and 39 were included. CLD/BPD is a significant independent risk factor for RSV hospitalization [RSVH (odds ratio 2.2-7.2); high SOE]. Infants and young children with CLD/BPD had high RSVH rates which were generally similar in Europe, the United States, and Canada, mostly varying between 12 and 21%. Infants with CLD also had a longer length of hospital stay than other high-risk groups and term infants (high SOE). On average, infants spent 4-11 days in hospital (moderate SOE). Once hospitalized for RSV, affected children were at risk for a more severe course of disease than children with no RSVH (moderate SOE).

Conclusion: Severe RSV infection in infants and young children with CLD/BPD poses a significant health burden in Western countries. Further studies focussing on the burden of RSV infection in this well-recognized population at high risk for severe disease are needed to help improve outcomes and plan allocation of healthcare resources.

Funding: AbbVie.

Citing Articles

An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.

Servadio M, Finocchietti M, Vassallo C, Cipelli R, Heiman F, Di Lucchio G Ital J Pediatr. 2024; 50(1):56.

PMID: 38528568 PMC: 10962102. DOI: 10.1186/s13052-024-01627-8.

Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem.

Singh S, Maheshwari A, Namazova I, Benjamin J, Wang Y Newborn (Clarksville). 2024; 2(3):222-234.

PMID: 38348152 PMC: 10860331. DOI: 10.5005/jp-journals-11002-0073.

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.

Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S Lancet Reg Health Am. 2023; 28:100629.

PMID: 38026446 PMC: 10663690. DOI: 10.1016/j.lana.2023.100629.

Association between prenatal and neonatal risk factors and development of bronchiolitis in early life.

Chen P, Tsai Y, Yu H, Hung C, Chen W, Lin C Asia Pac Allergy. 2023; 13(1):10-14.

PMID: 37389101 PMC: 10166242. DOI: 10.5415/apallergy.0000000000000002.

Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions.

Globenko A, Kuzin G, Rydlovskaya A, Isaeva E, Vetrova E, Pritchina T Front Pharmacol. 2023; 14:1087850.

PMID: 37214455 PMC: 10196389. DOI: 10.3389/fphar.2023.1087850.

References

Medici M, Arcangeletti M, Rossi G, Lanari M, Merolla R, di Luzio Paparatti U . Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol. 2006; 29(1):35-43. View

Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S . Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child. 2001; 85(6):463-8. PMC: 1719001. DOI: 10.1136/adc.85.6.463. View

Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O . Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2004; 90(1):F64-8. PMC: 1721807. DOI: 10.1136/adc.2003.029710. View

Piedimonte G, Perez M . Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014; 35(12):519-30. PMC: 5029757. DOI: 10.1542/pir.35-12-519. View

Ricart S, Marcos M, Sarda M, Anton A, Munoz-Almagro C, Pumarola T . Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol. 2012; 48(5):456-63. PMC: 7167901. DOI: 10.1002/ppul.22633. View

Deshpande S, Northern V . The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child. 2003; 88(12):1065-9. PMC: 1719378. DOI: 10.1136/adc.88.12.1065. View

Maitre N, Ballard R, Ellenberg J, Davis S, Greenberg J, Hamvas A . Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol. 2015; 35(5):313-321. PMC: 4414744. DOI: 10.1038/jp.2015.19. View

Wang E, Law B, Robinson J, Dobson S, Al Jumaah S, Stephens D . PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997; 99(3):E9. DOI: 10.1542/peds.99.3.e9. View

Pedersen O, Herskind A, Kamper J, Nielsen J, Kristensen K . Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark. Acta Paediatr. 2003; 92(2):240-2. DOI: 10.1111/j.1651-2227.2003.tb00533.x. View

10.

Simon A, Ammann R, Wilkesmann A, Eis-Hubinger A, Schildgen O, Weimann E . Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr. 2007; 166(12):1273-83. DOI: 10.1007/s00431-007-0426-y. View

11.

Berger T, Aebi C, Duppenthaler A, Stocker M . Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection. 2009; 37(2):109-16. DOI: 10.1007/s15010-008-8130-z. View

12.

Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon J . Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2005; 23(12):1081-5. View

13.

Flamant C, Hallalel F, Nolent P, Chevalier J, Renolleau S . Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr. 2005; 164(2):93-8. DOI: 10.1007/s00431-004-1580-0. View

14.

Boyce T, Mellen B, Mitchel Jr E, Wright P, Griffin M . Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000; 137(6):865-70. DOI: 10.1067/mpd.2000.110531. View

15.

Figueras Aloy J, Carbonell Estrany X . [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections]. An Pediatr (Barc). 2014; 82(3):199.e1-2. DOI: 10.1016/j.anpedi.2014.10.004. View

16.

Gil-Prieto R, Gonzalez-Escalada A, Marin-Garcia P, Gallardo-Pino C, Gil-de-Miguel A . Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study. Medicine (Baltimore). 2015; 94(21):e831. PMC: 4616425. DOI: 10.1097/MD.0000000000000831. View

17.

Simon A, Muller A, Khurana K, Engelhart S, Exner M, Schildgen O . Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection--results from a prospective multicenter German surveillance study. Int J Hyg Environ Health. 2007; 211(3-4):241-50. DOI: 10.1016/j.ijheh.2007.07.020. View

18.

Poindexter B, Feng R, Schmidt B, Aschner J, Ballard R, Hamvas A . Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc. 2015; 12(12):1822-30. PMC: 4722827. DOI: 10.1513/AnnalsATS.201504-218OC. View

19.

NORTHWAY Jr W, ROSAN R, Porter D . Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7):357-68. DOI: 10.1056/NEJM196702162760701. View

20.

Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Zweygberg Wirgart B . Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002; 91(5):593-8. DOI: 10.1080/080352502753711740. View